Saturday 17 October 2026 Export TYRA’s income statement to Excel — free account

Tyra Biosciences, Inc.

In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

18.52 0.52 −2.73%

Follow TYRA

Alert me

Market cap: $1.3B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.02

Total sells 10.59

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	1	—
Sell	3	2	1	1	1	—	—	—	—	—	—	—

Insider Ownership 30.64%

Capital & Financial Ratios $m

Market Cap 1,310.00

Revenue —

Net Income (148.56)

Free Cash Flow (109.90)

Net Debt (353.94)

Current Ratio 14.91

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.46

Past 5Y EPS Growth —

This Y EPS Growth (31.94%)

Next Y EPS Growth (5.58%)

Next Y revenue growth —

Next 5Y EPS Growth (16.83%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 77.03%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	203	341	256	354
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	212	347	265	367

	2023	2024	2025	Q'26
Payables	5	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	15	15	18	25

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.17%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(33)	(31)	—	—	—
’25	(25)	(24)	(22)	(24)	(95)
’24	(22)	(10)	(18)	(20)	(70)
’23	(10)	(10)	(17)	(14)	(50)
’22	(9)	(17)	(12)	(12)	(50)
’21	(5)	(4)	(6)	(9)	(24)
’20	(1)	(2)	(5)	(3)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(33)	(31)	—	—	—
’25	(25)	(24)	(22)	(24)	(95)
’24	(22)	(11)	(18)	(20)	(70)
’23	(10)	(10)	(17)	(14)	(51)
’22	(9)	(17)	(12)	(12)	(51)
’21	(5)	(5)	(6)	(9)	(24)
’20	(1)	(2)	(5)	(3)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.64)	(0.69)	—	—	—
’25	(0.47)	(0.47)	(0.50)	(0.57)	(2.01)
’24	(0.35)	(0.32)	(0.41)	(0.43)	(1.51)
’23	(0.28)	(0.31)	(0.49)	(0.53)	(1.62)
’22	(0.36)	(0.36)	(0.30)	(0.31)	(1.32)
’21	(2.10)	(2.43)	(0.72)	(0.24)	(1.91)
’20	(0.03)	(0.04)	(1.47)	—	(6.05)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	11.37	4.93	6.55	11.24	6.42	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	31.36	14.27	19.74	29.60	26.41
People
People	Employees	—	—	—	—	16	25	38	49	60	87
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(4)	(9)	(26)	(55)	(69)	(86)	(120)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(4)	(9)	(26)	(55)	(69)	(86)	(120)
	Depreciation	—	—	—	0	0	0	0	0	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.10)	(6.05)	(1.91)	(1.32)	(1.62)	(1.51)	(2.01)
	Cash flow	—	—	—	(0.06)	(5.03)	(1.72)	(1.20)	(1.17)	(1.22)	(1.60)
	Capex	—	—	—	0.00	(0.20)	(0.05)	(0.01)	(0.02)	(0.01)	0.00
	Free cash flow	—	—	—	(0.06)	(5.24)	(1.77)	(1.21)	(1.19)	(1.23)	(1.60)
	Book value	—	—	—	(0.11)	(8.84)	21.90	6.16	4.78	6.00	4.35
	Shares, m	—	—	—	43	2	14	42	43	57	60
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(3)	(8)	(24)	(50)	(50)	(70)	(95)
	Capex	—	—	—	0	0	(1)	(1)	(1)	(1)	0
	Free cash flow	—	—	—	(3)	(8)	(24)	(51)	(51)	(70)	(95)
Balance, $m
Balance, $m	Working capital	—	—	—	(5)	13	300	252	196	333	247
	Total debt	—	—	—	0	28	1	3	—	—	—
	Net debt	—	—	—	0	(15)	(302)	(251)	(203)	(341)	(256)
	Shareholders’ equity	—	—	—	(5)	(14)	302	258	204	343	259
Returns, %
Returns, %	ROA	—	—	—	(1,539.77)	(112.90)	(16.30)	(19.31)	(28.10)	(29.34)	(37.13)
	ROIC	—	—	—	0.00	0.00	0.00	(556.67)	(6,300.84)	(3,807.64)	(2,614.25)
	ROE	—	—	—	44.24	101.59	(18.25)	(19.77)	(29.92)	(31.60)	(39.83)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR	$1.4B	—	—	—	—	+17.74% (above 0%: growing)	—	—	Compare
OMER Omeros Corporation	$1.4B	9.5×	2.1×	+35.46% (above 0%: growing)	n/m	+118.70% (above 0%: growing)	97.20%	0.26%	Compare
INBX Inhibrx Biosciences, Inc.	$1.3B	— (loss-making)	— (loss-making)	+992.44% (above 0%: growing)	n/m	+0.12% (above 0%: growing)	100.00%	0.00%	Compare
ORIC Oric Pharmaceuticals, Inc.	$1.3B	— (loss-making)	—	—	n/m	−3.42% (below 0%: shrinking)	0.00%	0.00%	Compare
TYRA Tyra Biosciences, Inc.	$1.3B	— (loss-making)	—	—	n/m	−31.34% (below 0%: shrinking)	0.00%	0.00%
GHRS GH Research PLC	$1.3B	— (loss-making)	—	—	n/m	−66.62% (below 0%: shrinking)	0.00%	0.00%	Compare
NKTR Nektar Therapeutics	$1.3B	— (loss-making)	— (loss-making)	−9.34% (below 0%: shrinking)	n/m	−65.73% (below 0%: shrinking)	100.00%	(417.94%)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%	Compare
SNDX Syndax Pharmaceuticals, Inc.	$1.2B	— (loss-making)	— (loss-making)	+91.76% (above 0%: growing)	n/m	+65.47% (above 0%: growing)	95.59%	(54.95%)	Compare
Median of peers	$1.3B	—	—	+63.61%	—	−1.65%	95.59%	0.00%

All 614 Biotechnology stocks →

Tyra Biosciences, Inc. (TYRA) key facts

Concern: Tyra Biosciences, Inc. reported a net loss of $119.9 million, or a loss of $2.01 per share, for fiscal 2025.
Tyra Biosciences, Inc. (TYRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TYRA traded at $18.52, a market capitalization of $1.3 billion.
Return on equity was −39.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.